De Jongh J, Nieboer R, Schröders I, Seinen W, Van den Berg M
Research Institute of Toxicology, University of Utrecht, The Netherlands.
Arch Toxicol. 1993;67(9):598-604. doi: 10.1007/BF01974066.
Six groups of C57BL/6J mice received single oral doses of 1.5-10.6 nmol/kg 1,2,3,7,8-pentachlorodibenzo-p-dioxin (PnCDD), 1,2,3,6,7,8-hexachlorodibenzo-p-dioxin (HxCDD) or 2,3,4,7,8-pentachlorodibenzofuran (PnCDF) as single compounds or in combination with 300 mumol/kg 2,2',4,4',5,5'-hexachlorobiphenyl (HxCB). Two other groups of mice received a mixture of the first three compounds, either with or without HxCB. The hepatic deposition and elimination of the compounds and their CYP1a dependent 7-ethoxyresorufin-O-deethylation (EROD) activity were studied until day 175. Interactive effects on the hepatic deposition of PnCDD were observed in most of the mixed dose groups. For HxCDD and PnCDF interactive effects were either very small or absent. No interactive effects were observed on hepatic elimination rates of PnCDD, HxCDD or PnCDF. No evidence was found for the influence of HxCB cotreatment on the hepatic concentration-response curves of the three compounds or their mixture. Based on the results from the present study it is concluded that PCDDs, PCDFs and PCBs may influence each other's, toxicokinetics when administered in mixtures.
六组C57BL/6J小鼠分别单次口服剂量为1.5 - 10.6纳摩尔/千克的1,2,3,7,8 - 五氯二苯并 - p - 二恶英(PnCDD)、1,2,3,6,7,8 - 六氯二苯并 - p - 二恶英(HxCDD)或2,3,4,7,8 - 五氯二苯并呋喃(PnCDF),这些化合物可以单独使用,也可以与300微摩尔/千克的2,2',4,4',5,5' - 六氯联苯(HxCB)联合使用。另外两组小鼠接受前三种化合物的混合物,其中一组含HxCB,另一组不含HxCB。研究了这些化合物在肝脏中的沉积和消除情况以及它们依赖CYP1a的7 - 乙氧基异吩恶唑酮 - O - 脱乙基酶(EROD)活性,直至第175天。在大多数混合剂量组中观察到对PnCDD肝脏沉积的交互作用。对于HxCDD和PnCDF,交互作用非常小或不存在。未观察到对PnCDD、HxCDD或PnCDF肝脏消除率的交互作用。未发现HxCB联合处理对这三种化合物或其混合物的肝脏浓度 - 反应曲线有影响。基于本研究结果得出结论,多氯二苯并二恶英、多氯二苯并呋喃和多氯联苯在混合给药时可能会相互影响彼此的毒代动力学。